ViVac Pharma receives NIS 100,000 award for its work on programmable RNA immunotherapies targeting solid tumors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results